USPTO 2015–2025 USPTO PatentsView US Corporation

Spigen, Inc.

USPTO PatentsView assignee record - 49 granted patents across 0 technology areas, recorded in grant years 2019–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength.

RSS updates for this company

The verdict

According to USPTO PatentsView, Spigen ranks #6,843 of 49,997 tracked US assignees by granted-patent volume, with 49 patents across 0 technology areas.

#6,843
of 49,997 US assignees by volume
3rd percentile
by Innovation Score (14.6/100)
1.0
avg claims per patent
+413%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6843 · US Corporation #6,843 · 49 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-UNK · INNOV-LOW · CLAIMS-SPARSE · TYPE-USCORP · VEL-SURGE · BOOK-RICH

  • GRANTS-SMALL 49 grants
  • UPPER-Q #6,843/49,997
  • PHOTO-FINISH SenoRx
  • CPC-UNK CPC blank
  • INNOV-LOW 14.6/100
  • CLAIMS-SPARSE 1.0 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +413% vel
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: SenoRx, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Spigen’s 14.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Spigen

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Spigen's Innovation Score is 14.6/100 (3rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Spigen?

Each dot is one of Spigen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Spigen’s own 1.0 claims/patent is at or below the 15.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Spigen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 48.949.049.04949.049.049.1 0102030 Granted patents (volume) Avg claims / patent SenoRx, Inc. - 49, 13.14SenorxSigray, Inc. - 49, 24.73SigraySkylo Technologies, Inc. - 49, 20.18SkyloSomaLogic, Inc. - 49, 15.55SomalogicStubHub, Inc. - 49, 18.63StubhubTCL Technology Group Corporation - 49, 16.53TCL Technology Gr…THE Wiremold Company - 49, 13.9THE WiremoldTerumo Cardiovascular Systems Corporation - 49, 13.16Terumo Cardiovasc…Spigen, Inc. - 49, 1Spigen
Spigen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Spigen's grants concentrate

Spigen, Inc. is a focused PatentsView assignee: 0 CPC subclasses . Peak complete grant year is 2020 (32 grants) versus a trough of 3 in 2022. By volume, Spigen sits between SenoRx, Inc. and Terumo Cardiovascular Systems Corporation.

Spigen's three-year grant acceleration

From 2019–2021 to 2022–2024, Spigen, Inc. moved from 46 to 3 grants (0.07x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Who files at Spigen's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Spigen holds 49 patents at rank #6,846, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Spigen

By rank, the assignees closest to #6,846 in granted patent volume.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Spigen, neither rank-band nor same-CPC leaders (those blocks stay above).

Spigen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

15 3rd percentile higher than 3% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

010203040 2019202020212022 3
USPTO utility patent grants by year · 2019–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Spigen, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 8 16.3%
2020 32 65.3%
2021 6 12.2%
2022 3 6.1%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Spigen, Inc.'s patent record in context - here's where to go next.

  • Ranked #6,843 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Spigen, Inc. against SenoRx, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 14.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.